J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised

EarningspositiveDarzalexTremfyaPositive

AI Analysis

Summary

Johnson & Johnson reported Q2 earnings that beat expectations, driven by strong growth in Darzalex and Tremfya. The company raised its 2026 financial outlook.

Financial Highlights

Guidance

2026 outlook raised

Outcome Details

Q2 earnings beat with growth in Darzalex and Tremfya

Importance:6/10

Sentiment:

0.70

earningsguidanceoncologydermatology

Related Companies

$JNJ

Read the original article

Published by yahoo_finance on July 15, 2026 2:50 PM

Read Original